The ASGCT data provides mechanistic validation for agenT-797's dual-mode activity, de-risking the platform and supporting the upcoming Phase 2 trial in acute lung injury. Monitor for preliminary Phase 2 data in 2026, which could be a major catalyst. The broad applicability across oncology and critical care expands the addressable market.
Price Chart
Executive Summary
MiNK Therapeutics presented data at ASGCT 2026 showing its off-the-shelf iNKT cell therapy, agenT-797, produced context-dependent immune responses (pro-inflammatory in cancer, anti-inflammatory in ARDS) from the same manufacturing batch without genetic engineering. The data supports advancement into a randomized Phase 2 trial in acute lung injury, with preliminary results expected in 2026.
Key Facts
- agenT-797 drove TH1 pro-inflammatory immune program in 34 solid tumor patients and TH2 anti-inflammatory response in 20 ARDS patients from the same donor batch.
- Data includes complete metastatic remission in germ cell testicular cancer (agenT-797 + anti-PD-1) and improved survival/pathogen clearance in severe ARDS.
- Favorable safety profile: no uncontrolled cytokine release syndrome or pathologic hyperinflammation.
- Company advancing to randomized Phase 2 trial in acute lung injury (C-1300-02) with preliminary data expected in 2026.
- Manufacturing platform scalable: reproducible across multiple batches and donors, producing billions of cells per donor.
Financial Impact
No financial figures disclosed; potential value depends on Phase 2 trial outcomes and eventual commercialization.
Risk Factors
- Phase 2 trial results may not replicate Phase 1/2 findings.
- Competition from other cell therapy platforms and existing ARDS treatments.
- Regulatory and manufacturing scale-up risks for allogeneic cell therapy.
- Company has limited cash runway (market cap $55M) and may need to raise capital.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292728 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 13, 2026 7w ago | Press Release | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 6, 2026 8w ago | Press Release | $11.00 $11.23 | ▲ +2.09% | ▲ +1.49% | $12.44 (+13.09%) |
May 28, 2026 18w ago | Press Release | $12.20 $11.64 | ▼ −4.59% | ▼ −1.45% | $12.44 (+1.97%) |
May 20, 2026 19w ago | Press Release | $10.72 $12.14 | ▲ +13.25% | ▲ +12.51% | $12.44 (+16.04%) |
May 15, 2026 20w ago | 8-K | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 15, 2026 20w ago | Press Release | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 14, 2026 20w ago | Press Release | $10.51 $12.02 | ▲ +14.37% | ▲ +15.23% | $12.44 (+18.36%) |
May 12, 2026 20w ago | Press Release | $11.41 $12.19 | ▲ +6.84% | ▲ +8.56% | $12.44 (+9.03%) |
May 8, 2026 20w ago | Press Release | $10.95 $11.82 | ▲ +7.95% | ▲ +8.25% | $12.44 (+13.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access